Safety and Feasibility Assessment of a Pharmacy-Driven AUC/MIC Vancomycin Dosing Protocol in a Multicenter Hospital

Morgan Phillips1, Jeremy Rose1, Ashlee Hamel2

  • 1Sentara RMH Medical Center, Harrisonburg, Virginia, USA.

Microbiology Spectrum
|February 25, 2023
PubMed

Insights

Pharmacy-driven vancomycin dosing using area under the concentration-time curve to MIC (AUC/MIC) showed no difference in acute kidney injury (AKI) rates compared to traditional trough-based dosing. This approach improved lab draw convenience for healthcare personnel.

Area of Science:

  • Pharmacology
  • Nephrology
  • Infectious Diseases

Background:

  • Vancomycin is crucial for Gram-positive infections, including MRSA.
  • 2020 guidelines recommend an AUC/MIC target of 400-600 for vancomycin.
  • Implementing AUC/MIC dosing protocols is a focus in optimizing vancomycin therapy.

Purpose of the Study:

  • To compare the incidence of acute kidney injury (AKI) between pharmacy-driven AUC/MIC vancomycin dosing and traditional trough-based dosing.
  • To evaluate secondary outcomes including vancomycin duration, hospital length of stay, and laboratory monitoring efficiency.

Main Methods:

  • A retrospective study across 12 hospitals implementing a pharmacy-driven AUC/MIC vancomycin dosing protocol.
  • AKI was assessed using modified AKIN criteria and vancomycin guideline definitions.
  • Inferential statistics were used to analyze AKI rates and other clinical outcomes.

Main Results:

  • No significant difference in AKI rates was observed between AUC/MIC and trough-based vancomycin dosing (P=0.309 for AKIN, P=0.258 for guideline definition).
  • AUC/MIC dosing led to a higher proportion of vancomycin lab draws during standard times (52% vs. 24%, P < 0.05).
  • AUC/MIC dosing was associated with more labs drawn per person and less total vancomycin use.

Conclusions:

  • Pharmacy-driven AUC/MIC vancomycin dosing is not associated with increased AKI compared to trough-based dosing.
  • AUC/MIC dosing enhances laboratory monitoring efficiency, offering convenience for healthcare staff.
  • This multicenter study reflects real-world vancomycin use and suggests broad applicability for AUC/MIC dosing feasibility.

Related Concept Videos

One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance00:56

One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance

Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
118
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
276
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution01:09

One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution

The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
403
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation01:24

One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation

This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
622
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.2K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.7K